Synergistic pharmacological interactions emerge with Api enhancing antitumor drug efficacy while reducing toxicity: gemcitabine-Api coadministration exerts superior tumor growth inhibition compared to monotherapy in neoplastic cell lines (Johnson and Gonzalez de Mejia, 2013), yet paradoxically, kaempferol-Api combination only suppresses tumor growth in vitro while increasing tumor burden in vivo (Tang et al., 2017). The gene discussed is SERPINF2; the disease is neoplasm.